The guidelines address the following opportunistic infections: PCP, Toxo, Cryptosporidia, Microsporidia, TB, MAC, Bacterial Respiratory Disease, Bacterial Enteric Disease, Bartonella, Syphilis, Candida, Endemic Mycoses (Cryptococcosis, Histo, Cocci, Aspergillus) CMV, Non-CMV Herpes (HSV, VZV, HHV-8) HPV, HBV, HCV, PML/JCV, and Geographic OIs of Specific Consideration (Malaria, Penicilliosis, Leishmania, Chagas, Isospora).

Recommendations in this report cover:

• Preventing exposure to opportunistic pathogens; 
• Preventing disease; 
• Discontinuing primary prophylaxis after immune reconstitution; 
• Treating disease; 
• When to start ART in the setting of an acute OI; 
• Monitoring for adverse effects (including immune reconstitution inflammatory syndrome [IRIS]); 
• Managing treatment failure; 
• Preventing disease recurrence ("secondary prophylaxis" or chronic maintenance therapy); 
• Discontinuing secondary prophylaxis after immune reconstitution; and 
• Special considerations during pregnancy. 

Slide sets to accompany the guidelines are available from the National Coordinating Resource Center.